



Form PTO-1449 (Rev. 3-03)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 00509/2/US		Application Number 10/414,852	
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor Kevin E. Henegar			
				Filing Date April 16, 2003		Group Art Unit Unknown	
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
<i>K</i>		US 6,121,451	Sep 19, 2000	Henegar et al.	546	92	
Examiner: <i>Raymond Cornette</i>				Date Considered: <i>11/28/03</i>			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



BEST AVAILABLE COPY

Sheet 1 of 1

Form PTO-449 (Rev. 8-88)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 00509/2/US	Serial No. 10/414,852
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Henegar, K.E.	
				Filing Date April 16, 2003	
				Group No. 1614	
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)					
74		Joslen <i>et al.</i> (1998) A general synthetic approach to the (20S)-camptothecin family of antitumor agents by a regiocontrolled cascade radical cyclization of aryl isonitriles. Chemistry – A European Journal 4(1), 67–83.			
Examiner <i>Raymond G. Goff</i>		Date Considered <i>11/20/03</i>			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					